Navigation Links
Prostate Cancer Vaccine Looks Promising in Early Trial
Date:5/18/2008

Could help men with metastatic, recurring disease, researchers say

SUNDAY, May 18 (HealthDay News) -- A therapeutic vaccine to treat prostate cancer appears safe and may be effective, according to the results of an early trial.

The vaccine could give hope to men with metastatic prostate cancer by activating their immune systems to fight the disease. The vaccine was developed to enable a patient's immune system to produce anti-antigens and attack cancer cells, which can improve quality of life and extend survival.

"The primary objective of the study was to determine whether or not the vaccine was safe or whether it induced any serious adverse events," said lead researcher Dr. David Lubaroff, director of urology research at the University of Iowa. "The vaccine was quite safe."

In addition, the researchers wanted to see if the vaccine produced an immune response to prostate specific antigen (PSA).

"We found that 68 to 70 percent of the patients in the trial demonstrated immune responses to PSA," Lubaroff said. "This was their last resort, and we were encouraged by the fact that we could detect any immune response in these patients."

Results of the phase 1 trial were expected to be presented Sunday at the American Urological Association annual meeting, in Orlando, Fla.

In the trial, Lubaroff's team tested the adenovirus/PSA vaccine in 32 men with metastatic prostate cancer. The men were treated with one of three different doses of the vaccine and followed for 12 months.

In addition to developing immune responses to PSA, 57 percent of the patients survived longer than predicted. Forty-eight percent actually doubled their expected life span. The longest survival was almost six years, the researchers reported.

Based on these results, Lubaroff's group has started a phase II trial, which will determine whether the immune response and survival seen in this trial is really therapeutically meaningful in a larger number of patients.

"If this vaccine proves to induce a strong anti-PSA immune response, and if there is a correlation between this PSA response and an effect on the disease, then we could use this vaccine as another therapy," Lubaroff said.

One expert is skeptical that this vaccine will ever prove to be a viable treatment.

"I think about all you can prove from this kind of study is safety," said Dr. Bruce Roth, a professor of medicine and urology at Vanderbilt University. "But that's a world of difference from saying that there is evidence of efficacy."

Roth doesn't think changes in PSA in this kind of trial are enough to prove the vaccine works.

"I would not take away from this that this is the breakthrough we have been waiting for, for 35 years," Roth said. "It's an OK theory, but we have been disappointed a lot in the past couple of decades with immune therapies that look great but never produce the results we had hoped for."

Another study expected to be presented Sunday showed that a PSA reading taken between the ages of 45 and 50 actually helps predict prostate cancer up to 30 years later. These findings suggest that prostate cancer may start to develop very early and that PSA levels affect the development of prostate cancer.

A third study found that black men who have a family history of prostate cancer could benefit from a PSA reading, which could determine their probability of developing the disease.

Black men who have known risks for prostate cancer and higher levels of PSA are more likely to develop the disease, compared with people in the general population.

However, black men with a family history of prostate cancer are unlikely to develop the disease if their baseline PSA was below what is normal for their age. The effect of family history and PSA level actually overrode other prostate cancer risk factors, the researchers said.

More information

For more on prostate cancer, visit the American Cancer Society.



SOURCES: David Lubaroff, M.D., director, Urology Research, and professor, urology and microbiology, University of Iowa, Iowa City; Bruce Roth, M.D., professor, medicine and urology, Vanderbilt University, Nashville, Tenn.; May 18, 2008, presentation, American Urological Association annual meeting, Orlando


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prostate Cancer Vaccine Looks Promising in Early Trial
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there ... Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK ... In doing so, it offers an effective alternative to traditional braces. As a result, ...
(Date:7/26/2017)... 92660 (PRWEB) , ... July 26, 2017 ... ... Prevention for on-premises, off and in the cloud ; today announced the availability ... scientific algorithms within a simple to use control console for Data Discovery, Classification, ...
(Date:7/26/2017)... ... July 26, 2017 , ... A global center of ... The state of the art center will provide advanced surgical care (heart ... of providing heart patients longer lives. , North American Veterinary Heart Center, the ...
(Date:7/26/2017)... ... 2017 , ... The Amnesty Rally 2017 will be held on Saturday, July ... Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens & Zoo). , ... throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation guns to law enforcement ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults ... United States, but ways to improve asthma control in the population are not well ... Practice (JACI: In Practice), an official journal of the American Academy of Allergy, Asthma ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... Mich. , July 13, 2017  Centurion Medical Products, a ... its DisImpactor ® fecal impaction removal device for hospice patient ... ... Patient pain management and ... for Hospice can help alleviate patient pain while preventing unneeded emergency ...
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
Breaking Medicine Technology: